Juniper Pharmaceuticals is healthcare company with core businesses consisting of its Crinone® (progesterone gel) franchise. Co. has two segments: product, which oversees the supply chain and manufacturing of Crinone®, an 8.0% progesterone bioadhesive vaginal gel designed for progesterone supplementation or replacement as part of an assisted reproductive technology treatment for infertile women with progesterone deficiency; and service, which includes pharmaceutical development, clinical trial manufacturing, and analytical and consulting services for Co.'s customers, as well as characterizing and developing pharmaceutical product candidates for Co.'s internal programs. The JNP average annual return 10 years is shown above.
The Average Annual Return on the JNP average annual return 10 years page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether JNP average annual return 10 years or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the JNP average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|